Comparison between Pulsed High-Dose Dexamethasone and Daily Corticosteroid Therapy for Adult Primary Immune Thrombocytopenia: A Retrospective Study

Kumi Nakazaki1,2, Masataka Hosoi1, Akira Hangaishi1, Motoshi Ichikawa1, Yasuhiro Nannya1 and Mineo Kurokawa1

Abstract

Objective Recently, pulsed high-dose dexamethasone (HD-Dexa) therapy was proposed as a possible alteration for the classical prednisolone (PSL) therapy for primary immune thrombocytopenia (ITP) patients, however it remains to be confirmed which of these remedies is superior. So the objective of this study is to compare the efficacy and the sustainability of these options.

Methods The first-line therapy at our institute for untreated adult ITP cases was accordingly changed as follows, and we retrospectively evaluated the outcomes: 1) daily administration of 0.5-1 mg/kg PSL for 2-4 weeks and subsequently stepwise reduction, 2) one course of HD-Dexa (40 mg/day for four consecutive days, 1xHD-Dexa), 3) three courses of the same dose of HD-Dexa (3xHD-Dexa) repeated biweekly. This study was approved by the ethical committee of the University of Tokyo.

Results Twenty-five patients were enrolled consecutively. A good initial response was attained through all the regimens. Meanwhile, time to next treatment for lack of response or relapse was significantly longer in the PSL group than in the other groups (log-rank test, PSL vs. 1xHD-Dexa p<0.001, PSL vs. 3xHD-Dexa p=0.0053, respectively). Additionally, PSL regimen conferred a significantly longer duration time of response (PSL vs. 1xHD-Dexa p=0.0024, PSL vs. 3xHD-Dexa p=0.028, respectively) and CR (PSL vs. 1xHD-Dexa p=0.012, PSL vs. 3xHD-Dexa p=0.0090, respectively). No patient discontinued the treatment due to side effects in this study.

Conclusion PSL regimen was considered to be superior to pulsed HD-Dexa regimens in the sustainability of response.

Key words: primary immune thrombocytopenia, ITP, high-dose dexamethasone, prednisolone

(DOI: 10.2169/internalmedicine.51.7005)

Introduction

Poor long-term sustainability and possible adverse effects by long-time administration of corticosteroids were matters in dispute of the standard corticosteroid therapy for the first-line treatment of adult primary immune thrombocytopenia (ITP) (1, 2). Recently, several reports suggested that high-dose dexamethasone (HD-Dexa) therapy might be a possible alteration for the classical PSL therapy for newly diagnosed ITP patients (3-5). A high initial response of a single dose of HD-Dexa therapy was shown by Cheng et al. (4), and the Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) party demonstrated that three cycles of biweekly HD-Dexa pulses conferred a significantly longer duration of response (6). Indeed, the latest international consensus report and practice guideline for ITP proposed HD-Dexa therapy as one of the front-line options for ITP (2, 6).

According to these reports, the front-line therapy at our institute for untreated adult ITP patients was switched from
Table 1. Clinical Characteristics of 25 Patients with ITP

<table>
<thead>
<tr>
<th></th>
<th>PSL</th>
<th>1xHD-Dexa</th>
<th>3xHD-Dexa</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>number</td>
<td>8</td>
<td>12</td>
<td>5</td>
<td>0.39</td>
</tr>
<tr>
<td>(male/ female)</td>
<td>(3/5)</td>
<td>(6/ 6)</td>
<td>(4/ 1)</td>
<td></td>
</tr>
<tr>
<td>age (years)</td>
<td>70.5</td>
<td>53.5</td>
<td>51</td>
<td>0.37</td>
</tr>
<tr>
<td>median (range)</td>
<td>(31-86)</td>
<td>(21-75)</td>
<td>(41-61)</td>
<td></td>
</tr>
<tr>
<td>platelet count</td>
<td>(&lt;10^9/L)</td>
<td>5.5</td>
<td>7.0</td>
<td>5.0</td>
</tr>
<tr>
<td>(median (range)</td>
<td>(3-21)</td>
<td>(1-28)</td>
<td>(3-8)</td>
<td></td>
</tr>
<tr>
<td>H. pylori infection (%)</td>
<td>(50%)</td>
<td>(25%)</td>
<td>(40%)</td>
<td></td>
</tr>
<tr>
<td>bleeding score</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>(0, absent; 1, 1, 2, 3)</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>(4, major)</td>
<td>3</td>
<td>5</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>(0, absent; 1, 2, 3)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

PSL indicates prednisolone; 1xHD-Dexa, one course of High-Dose Dexamethasone; 3xHD-Dexa, three courses of the same dose of High-Dose Dexamethasone; H. pylori, Helicobacter pylori; *H. pylori infection was tested by a urea breath test or a blood antibody test.

# Bleeding score was according to the definition of the report by the GIMEMA group (reference 5).

Patients

The newly diagnosed and untreated adult primary ITP patients at our institute from 2000 to 2010 were enrolled consecutively. The diagnosis was based on low platelet count with or without bleeding symptoms and normal to increased number of megakaryocytes in the bone marrow by aspiration. Patients with marrow dysplasia or other causes of thrombocytopenia including auto-immune diseases, liver cirrhosis, and other hematological diseases were excluded.

We applied interventions consecutively for patients with a platelet count of less than 30×10^9/L or with bleeding symptoms. We also excluded patients with pregnancy. Patients of secondary thrombocytopenia due to Helicobacter pylori (H. pylori) were excluded, who improved by eradication therapy of H. pylori despite inadequate recovery by steroid therapy alone, or who maintained platelet response after termination of steroids with successful eradication of H. pylori. Infection of H. pylori was tested through a urea breath test or a blood antibody test. Bleeding symptoms were classified from grade 0 to 4 according to the definition of the preceding report by the GIMEMA group as follows: 0, Absent bleeding; 1, Petechiae; 2, Ecchymoses and/or dripping with moderate loss of blood; 3, Major mucous hemorrhage with copious loss of blood without sequelae; 4, Major mucous and/or parenchymal hemorrhage with copious loss of blood with sequelae and/or life threatening or death (5).

Study protocol

The front-line therapies for untreated ITP were altered with time as follows: 1) daily administration of 0.5-1 mg/kg PSL for 2-4 weeks and subsequent reduction by 5-10 mg per 1-2 weeks to 5-10 mg/day while the platelet count was maintained, then followed by slower reduction of PSL from January 2000 until May 2004, 2) one course of HD-Dexa (40 mg per day for four consecutive days, denoted as 1xHD-Dexa) between June 2004 and March 2009, 3) three courses of the same dose of HD-Dexa (denoted as 3xHD-Dexa) repeated biweekly after April 2009 until December 2010. In the PSL group, the pace of dose reduction was finally decided at the discretion of attending physicians. Administration of antacids, antibiotics, and other interventions were applied to prevent probable adverse events. This study was approved by the ethical committee of the University of Tokyo.

We primarily evaluated the time to next treatment defined as the interval from the front-line regimens to salvage therapies for lack or loss of response of the former. We also examined response rate and its duration of each regimen according to the recommended criteria (7). Briefly, "response" was defined as any platelet count between 30 and 100×10^9/L, and at least doubling of the baseline count. "CR" was defined as any platelet count at least 100×10^9/L. "Response" also required concurrent resolution of bleeding symptoms. Duration time of response or CR was calculated from the time of response or CR achievement until loss of response.

Statistical analysis

Fisher’s exact test was applied to detect the difference of categorical variables including sex, H. pylori infection status, response rate and CR rate among regimens. Analysis of variance was performed for comparing age, platelet count at diagnosis, time span from therapy initiation to response achievement among the three regimens. Time to next treatment and duration time of response and CR were calculated using the Kaplan-Meier method and the difference between the groups was assessed by log-rank test.

Results

Patients

Twenty-five patients (13 males and 12 females) were enrolled consecutively in this study, and the median age was 55 years old (range, 21-86). Eight, twelve, and five people received treatment regimens of PSL, 1xHD-Dexa, and 3xHD-Dexa in accordance with the changes of the upfront regimens in the times, respectively (Table 1). However, two patients received PSL due to the complications or age when HD-Dexa was adopted. No significant differences were
found between these three groups in characteristics of patients. Median follow-up time was 32.2 months (range, 1.3-102.6 months). The clinical courses of all the cases are shown (Fig. 1). One, one, and two patients underwent eradication of *H. pylori* therapy during their scheduled treatment period in the PSL, 1xHD-Dexa, and 3xHD-Dexa groups, respectively. Eight cases of the PSL group were given median 3,069 mg (2,225-6,510 mg) of PSL in total in the scheduled period. No patients needed concomitant administration of intravenous immunoglobulin in this study.

**Efficacy**

A good initial response was achieved through all the regimens. Response rate was PSL: 100% (95% confidential interval: 63.1-100%), 1xHD-Dexa: 75% (42.8-94.5%), and 3xHD-Dexa: 100% (47.8-100%), and CR rate was PSL:
Table 2. Adverse Events

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>PSL (total/ Grade 3-4)</th>
<th>1xHD-Dexa (total/ Grade 3-4)</th>
<th>3xHD-Dexa (total/ Grade 3-4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>2/1</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>2/0</td>
<td>1/0</td>
<td>1/0</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Insomnia</td>
<td>1/0</td>
<td>2/0</td>
<td>1/0</td>
</tr>
<tr>
<td>Gastrointestinal pain</td>
<td>0/0</td>
<td>1/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Flushing</td>
<td>0/0</td>
<td>1/0</td>
<td>0/0</td>
</tr>
<tr>
<td>Others</td>
<td>1/1*</td>
<td>0/0</td>
<td>0/0</td>
</tr>
</tbody>
</table>

PSL indicates prednisolone; 1xHD-Dexa, one course of High-Dose Dexamethasone; 3xHD-Dexa, three courses of the same dose of High-Dose Dexamethasone;
* One patient with cardiac complication before treatment suffered atrial flutter in PSL group.

Side effects

In total, fourteen people had some kind of side effect (Table 2). Long-term unfavorable effects were not observed. No patient discontinued the treatment due to side effects related to therapy in this study.
Discussion

All three regimens conferred an initial good response, however, time to next treatment of the PSL group was significantly longer than those of the other two groups. This was attributed to a high incidence of early relapse in both of the HD-Dexa groups. Duration time of response and CR was significantly shorter in these groups than the PSL group.

A few studies for untreated ITP patients (3-5, 8, 9) and for refractory or pre-treated adult ITP patients (4, 10-15) have been reported regarding the efficacy of HD-Dexa regimens. Even with the difference of the criteria of response and the number of cycles of HD-Dexa, an initial response was obtained in more than 70% in the untreated groups. In the present analysis HD-Dexa regimens yielded a similar good response in comparison with historical data (3-5, 8). Meanwhile, as to time to next treatment, the duration time was short for the untreated ITP patients. The first-line therapy for untreated ITP patients at our institution was switched back to the PSL regimen considering the advantage of this group in the sustainability of response.

In addition, the rate of initial CR tended to be lower in the one course of HD-Dexa group than in the others. So, both in the initial response rate and sustainability of the obtained response, only one course of the regimen without additional therapy was estimated to be inadequate for treatment of ITP patients. The preceding report showed that repetition of HD-Dexa regimen improved the long-term outcome (5), however, in this study no significant difference was obtained between the HD-Dexa groups in time to next treatment and duration of time of response and CR.

A risk of chronic side effects due to an increased accumulated dose of corticosteroids by long-term administration of the medicine was one of the disputed points in selecting the front-line therapy against ITP. In this study chronic adverse effects did not occur. When the patients of 1xHD-Dexa and 3xHD-Dexa group completed the regimen, 160 mg and 480 mg of dexamethasone in total were given. These dosages correspond to 1,000 mg and 3,000 mg of PSL in glucocorticoid activity, respectively. Surprisingly median total dosage given to the PSL group was nearly equal to the converted amount of 3xHD-Dexa group during the scheduled period.

In conclusion, the standard PSL regimen was considered to be superior to HD-Dexa regimens in the sustainability of response, which was compatible with the very recent guideline for ITP (6). The present study suffered retrospective nature and low subject number, thus a prospective randomized study comparing PSL and HD-Dexa regimens is warranted.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We appreciate all the people concerned. K.N., M.H., A.H., and Y.N. designed the protocol and analyzed the data. K.N., M. H., and Y.N. wrote the paper. Y.N., M.I., and M.K. organized the study.

References


